PBYI
Puma Biotechnology, Inc.
PBYI trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over PBYI overall, supported by stronger valuation and lower modeled downside.
PBYI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Strong |
PBYI's cash flow and balance sheet are currently strong, and its revenue and profitability are stable.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PBYI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.4x | $2.49 | -69% |
| Fair | 12x | $5.71 | -29% |
| Current | 18x | $8.08 | — |
| Expensive | 22x | $10.08 | +25% |
Historical ranges are pointers, not guarantees.
PBYI's PE is in its expensive range at 18x.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over PBYI in the historical PE scenario, which offers more potential upside but is not a forecast.
PBYI Forward outlook
There aren't enough analyst estimates for PBYI to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PBYI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.46 | -39% |
| Q2 2026 | $0.52 | -47% |
| Q1 2026 | $0.48 | -38% |
| Q4 2025 | $0.61 | -1.6% |
| Q3 2025 | $0.75 | +60% |
| Q2 2025 | $0.99 | +450% |
| Q1 2025 | $0.78 | +144% |
| Q4 2024 | $0.62 | +38% |
PBYI has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
PBYI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.1M | +1.1% |
| Q2 2026 | $56.5M | +7.8% |
| Q1 2026 | $44.8M | -2.6% |
| Q4 2025 | $75.5M | +28% |
| Q3 2025 | $54.5M | -32% |
| Q2 2025 | $52.4M | +11% |
| Q1 2025 | $46M | +5.1% |
| Q4 2024 | $59.1M | -18% |
PBYI's revenue is growing: $55M last quarter, up 1.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -8 points |
| Q2 2026 | 13% | +0.8 points |
| Q1 2026 | -8.5% | -17 points |
| Q4 2025 | 23% | +0.1 points |
| Q3 2025 | 18% | -9.8 points |
| Q2 2025 | 13% | +17 points |
| Q1 2025 | 8.7% | +14 points |
| Q4 2024 | 23% | +2.1 points |
PBYI has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over PBYI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
PBYI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $14.6M | +51% |
| Q2 2026 | $1.6M | -88% |
| Q1 2026 | $15.4M | +334% |
| Q4 2025 | $14.5M | -7.3% |
| Q3 2025 | $9.7M | -12% |
| Q1 2025 | $3.6M | -68% |
| Q4 2024 | $15.6M | +50% |
| Q3 2024 | $11M | +4.1% |
PBYI has the edge over UNH on cash flow, with stronger typical year-over-year growth.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
PBYI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +520K shares |
| 1 year | +4.3% | +2.2M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +30% | +12.3M shares |
| Available history | +36% | +14.1M shares |
PBYI has 53M diluted shares, up 4.3% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PBYI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PBYI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.9x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.1x | Net Cash |
PBYI has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PBYI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.6 | Neutral |
| Stochastic | 35.7 | Neutral |
PBYI's weekly RSI is 46 (neutral) and its Stochastic is 36 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PBYI PE vs Healthcare Sector
| Metric | PBYI | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 32% below |
| PE % | 70 | 29 | 41 pts above |
PBYI has the edge over UNH on valuation relative to its sector.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PBYI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.65 | 16% below |
| 20 week MA | $9.11 | 11% below |
| 50 week MA | $7.65 | 5.6% above |
| 100 week MA | $5.72 | 41% above |
| 200 week MA | $4.69 | 72% above |
PBYI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 72% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PBYI on trend strength, trading above more of its moving averages.
PBYI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.66 | $11.4 | +32% |
| 2021 | $11.4 | $3.46 | -70% |
| 2022 | $3.46 | $4.12 | +19% |
| 2023 | $4.12 | $4.33 | +5.1% |
| 2024 | $4.33 | $3.08 | -29% |
| 2025 | $3.08 | $6.16 | +100% |
| 2026 YTD | $6.16 | $8.08 | +31% |
PBYI has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.